State-of-the-art acute and chronic GVHD treatment.

Int J Hematol

Division of Hematology and Oncology, University of Alabama at Birmingham (UAB), 1802 6th Ave South, NP 2562, Birmingham, AL, 35294-3300, USA.

Published: May 2015

Graft-versus-host disease (GVHD) remains as the major obstacle for successful hematopoietic stem cell transplant (HSCT). Roughly half of the patients undergoing HSCT develop GVHD which requires treatment, and above 10 % of the patient may die because of it. However, GVHD presents with anti-tumor activity, called graft-versus-tumor (GVT) effect, and it carries significant anti-tumor activity, thus suppressing GVHD completely may increase the relapse of original disease. Thus, it is important to control GVHD to the appropriate level.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-015-1785-1DOI Listing

Publication Analysis

Top Keywords

anti-tumor activity
8
gvhd
6
state-of-the-art acute
4
acute chronic
4
chronic gvhd
4
gvhd treatment
4
treatment graft-versus-host
4
graft-versus-host disease
4
disease gvhd
4
gvhd remains
4

Similar Publications

Inflammasomes are defense complexes that utilize cytokines and immunogenic cell death (ICD) to stimulate the immune system against pathogens. Inspired by their dual action, we present cytokine-armed pyroptosis as a strategy for boosting immune response against diverse types of tumors. To induce pyroptosis, we utilize designed tightly regulated gasdermin D variants comprising different pore-forming capabilities and diverse modes of activation, representing a toolbox of ICD inducers.

View Article and Find Full Text PDF

Metaplastic breast cancer (MpBC) is a highly chemoresistant subtype of breast cancer with no standardized therapy options. A clinical study in anthracycline-refractory MpBC patients suggested that nitric oxide synthase (NOS) inhibitor NG-monomethyl-l-arginine (L-NMMA) may augment anti-tumor efficacy of taxane. We report that NOS blockade potentiated response of human MpBC cell lines and tumors to phosphoinositide 3-kinase (PI3K) inhibitor alpelisib and taxane.

View Article and Find Full Text PDF

The increasing prevalence of dental pathogens and oral cancer calls for new therapeutic agents. Nanoparticle (NPs) based tumor therapy enables precise targeting and controlled drug release, improving anti-cancer treatment efficacy while reducing systemic toxicity. Zinc oxide NPs (ZnO NPs) are notable in nanomedicine for their exceptional physicochemical and biological properties.

View Article and Find Full Text PDF

Cancer, a disease threatening human life, is caused by the disturbance of the normal cell cycle, which results in the spontaneous growth of normal and malignant cells, the lack of differentiation between the two, and consequently malignant growths. Nowadays, various synthetic agents are applied for cancer therapy; nevertheless, reports have confirmed that these chemical agents are associated with various adverse complications. This experimental study was designed to assess the anti-tumor activities of zinc nanoparticles (ZnNPs) green synthesized by the () extract against Ehrlich solid tumors (EST) in mice.

View Article and Find Full Text PDF

Background: Melanoma cells frequently dedifferentiate in response to inflammation which can increase responses to certain cytokines. Interferon-γ (IFNγ) is an integral part of the anti-tumor immune response and can directly induce both differentiational changes and expression of immunosuppressive proteins in melanoma cells. How the differentiation status of melanoma cells affects IFNγ responses remains unclear.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!